Another randomized controlled clinical trial specifically focusing on their weight loss effects demonstrated that, in adults with overweight or obesity without diabetes, once-weekly subcutaneous injection of semaglutide resulted in significantly greater weight loss at 68 weeks compared with once-daily subcutaneous injection of liraglutide, and the incidence of gastrointestinal adverse reactions was similar between the two groups [Reference Rubino, Greenway, Khalid, ONeil, Rosenstock and Srrig47]
Important clinical note: GHK-Cu is not FDA-approved to treat, cure, or prevent any specific disease
Protective effects of sirtuin 3 in a murine model of sepsis-induced acute kidney injury
Key adverse effects include sexual dysfunction and, rarely, mood changes
Does injecting GLP-1 at night cause more sleep disruption
They should also be attuned to the importance of adhering to a healthy lifestyle as a cornerstone of chronic disease management, including weight loss and diabetes care